Ras proteins operate as molecular switches in signal transduction pathways downstream of tyrosine kinases and G-protein-coupled receptors. Ras is switched from the inactive GDP-bound state to the active GTP-bound state by guanine nucleotide exchange factors (GEFs). We report here the cloning and characterization of Ras-GRP2, a longer alternatively spliced form of the recently cloned RapGEF, CalDAG-GEFI. A unique feature of Ras-GRP2 is that it is targeted to the plasma membrane by a combination of N-terminal myristoylation and palmitoylation. In vivo, RasGRP2 selectively catalyzes nucleotide exchange on N-and Ki-Ras, but not Ha-Ras. RasGRP2 also catalyzes nucleotide exchange on Rap1, but this RapGEF activity is less potent than that associated with CalDAG-GEFI. The nucleotide exchange activity of Ras-GRP2 toward N-Ras is stimulated by diacylglycerol and inhibited by calcium. The effects of diacylglycerol and calcium are additive but are not accompanied by any detectable change in the subcellular localization of Ras-GRP2. In contrast, CalDAG-GEFI is localized predominantly to the cytosol and lacks Ras exchange activity in vivo. However, prolonged exposure to phorbol esters, or growth in serum, results in localization of CalDAG-GEFI to the cell membrane and restoration of Ras exchange activity. Expression of RasGRP2 or CalDAG-GEFI in NIH3T3 cells transfected with wild type N-Ras results in an accelerated growth rate but not morphologic transformation. Thus, under appropriate growth conditions, CalDAG-GEFI and RasGRP2 are dual specificity Ras and Rap exchange factors.
Ras proteins are small GTPases that operate as binary switches in key signal transduction pathways regulating cell proliferation and differentiation. The amount of active GTPbound Ras is in turn controlled by the actions of two classes of regulator, guanine nucleotide exchange factors (GEFs) 1 and
GTPase-activating proteins (GAPs) which activate and deactivate Ras, respectively. A number of RasGEFs have been cloned, which share a core catalytic exchange domain and probably release GDP from Ras via a common mechanism (1, 2 (4 -6) . Sos is normally localized to the cell cytosol, but is recruited to the plasma membrane in response to growth factor receptor activation. Since Ras must be localized at the plasma membrane in order to signal, Ras activation by Sos can be efficiently regulated by simply controlling the subcellular localization of Sos (7, 8) . Sos is recruited to the plasma membrane in complexes with the adapter proteins Grb2 and Shc (5, 6) , which bind to autophosphorylated tyrosine kinase receptors (9 -11) or to transphosphorylated docking proteins (12) . Similarly, G-protein-coupled receptors that activate Src and Shc can also recruit Grb2-Sos to the cell membrane and activate Ras (13, 14) . Although plasma membrane recruitment of Sos is sufficient to activate Ras, it is also clear that more complex intermolecular interactions also influence the activity of this exchange factor (15) (16) (17) (18) .
A second family of RasGEFs comprises the related proteins RasGRF1 and RasGRF2 (19, 20) . RasGRF1 is expressed only in the central nervous system, specifically in the synaptosomal fraction of neuronal cells (21) where it plays a role in the establishment of long term memory (22) . RasGRF2 is expressed both within and without the central nervous system (20) . In contrast to Sos, RasGRF1 is constitutively localized to the plasma membrane, probably anchored through its N-terminal pleckstrin homology domain (23) . RasGRF1 exchange activity is quiescent until activated by a rise in intracellular calcium (23, 24) . RasGRF2 is also regulated by calcium, but unlike RasGRF1, RasGRF2 is localized to the cytosol in resting cells until a rise in intracellular calcium levels causes relocalization of RasGRF2 to the cell periphery and activation of its exchange activity (20) . A feature common to Sos and RasGRF is the presence of Dbl homology domains comprising the catalytic core sequences of exchange factors for the Rho family of small GTPases (25) . The binding of phosphatidylinositol 3,4-bisphosphate to a pleckstrin homology domain flanking the Dbl homol-ogy domain of Sos1 activates exchange activity toward Rac (26) , indicating that such RasGEFs coordinate activation of Ras and Rho family proteins.
Most recently, a new family of Ras subfamily GEFs have been identified that are regulated by diacylglycerol and calcium. RasGRP (also referred to as CalDAG-GEFII) activates N-, Ha-, and Ki-Ras with varying efficiencies (27, 28) , whereas the closely related CalDAG-GEFI (also referred to as HCDC25L (Ref. 29) ) activates Rap1 but not Ha-Ras (30) . In generating a transcript map of chromosome 11q13 (31), we independently cloned CalDAG-GEFI and identified an additional 5Ј-coding exon. We report here the characterization of RasGRP2: the widely expressed, longer isoform of CalDAG-GEFI. We show that RasGRP2 is constitutively localized to the plasma membrane by N-terminal acylation, a feature not previously described for any RasGEF. A consequence of constitutive plasma membrane localization is that RasGRP2 operates as an exchange factor for N-Ras and Ki-Ras in addition to being an activator of Rap1. RasGRP2, like CalDAG-GEFI, cannot activate Ha-Ras. CalDAG-GEFI and RasGRP2 also show quite distinct responses to calcium, diacylglycerol, and serum stimulation revealing a series of interesting possibilities for coordinate regulation of Ras and Rap function.
EXPERIMENTAL PROCEDURES
Cloning of RASGRP2-Cosmid cSRL-20 h12, derived from a chromosome 11 cosmid library that contained the human MCG7 (RASGRP2) gene (31) , was sequenced and the sequence data aligned to the GenBank Expressed Sequence Tag (EST) data base using the program BLASTN (32) . The cDNA clones for matching EST entries T78563 (clone 113434) and AA035643 (clone 471819) were obtained from Genome Systems Inc. and sequenced to completion with gene-specific and vector-specific primers. The data base entry of a third matching EST clone, HIBBP12, contained an additional stretch of nucleotides upstream of the sequences of the other ESTs, and was therefore suspected to contain an additional upstream exon of RASGRP2, but since this clone was not commercially available the new exon was sought by PCR from a genomic template, bacterial artificial chromosome clone 137C7 (Genome Systems Inc). The composite cDNA sequence of RASGRP2 was suspected to contain a single nucleotide error originating from within clone 471819 and the correct nucleotide sequence was therefore sought by reverse transcription-polymerase chain reaction of the cDNA fragment from a human cDNA pool. The resulting PCR product was ligated into pGEM-T (Promega) and the clone, designated MCG7-pGEM, sequenced. The corrected nucleotide sequence of RASGRP2 was translated in all possible reading frames and compared with the nonredundant protein data base using the program BLASTX (32) . One open reading frame (ORF), encoding RasGRP2-609, was assigned on the basis of homology with the Caenorhabditis elegans protein F25B3.3 (GenBank accession no. Z70752) and is identical to HCDC25L (GenBank accession no. Y12336) (29) and CalDAG-GEFI (GenBank accession no. U78170) (30) . Conceptual translation of the ORF from the alternate translation start site upstream of the one utilized in RasGRP2-609, contained in the sequence from bacterial artificial chromosome clone 137C7, was designated RasGRP2-671. These sequences have been deposited under GenBank accession nos. AF043723 and AF043722, respectively.
Plasmid Construction-A Myc tag was cloned onto the N terminus of RasGRP2-609 by recombination of MCG7-pGEM, EST clone 113434, and pGEM-11Z-Myc-tag (33) to give clone Myc-RasGRP2-609 (referred to as Myc-CalDAG-GEFI hereafter). Myc-CalDAG-GEFI was digested with BamHI to remove the Myc tag and ligated into pGEX-2T (Amersham Pharmacia Biotech). The final construct has an ORF that fuses GST to the front of RasGRP2-609. A C-terminal Flag-tagged RasGRP2-671 cDNA was generated by PCR. The final Flag-tagged construct contains an ORF with the amino acids DYKDDDDKstop (Flag) added immediately after the last residue of RasGRP2 (hereafter referred to as RasGRP2-Flag). The Myc-and Flag-tagged constructs were directionally cloned into the eukaryotic expression vector EXV.
Ras Guanine Nucleotide Exchange Assays-In vitro and in vivo nucleotide exchange assays were performed as described previously (34, 35) .
Ras/Rap "Pull-down" Assays-Frozen cells were lysed in 200 l of ice-cold lysis buffer (0.5% Triton X-100, 0.5% deoxycholate, 20 mM TrisCl, pH 7.5, 150 mM NaCl, 1% aprotinin, 1 mM phenylmethylsulfonyl fluoride). Insoluble cellular debris was removed by centrifugation at 14,000 rpm for 5 min at 4°C. 10 l of the supernatant was reserved for later immunoblotting; the remainder was diluted in 1 ml of binding buffer (50 mM TrisCl pH7.5, 10 mM MgCl 2 , 0.5 mg/ml bovine serum albumin, 0.5 mM dithiothreitol, 100 mM NaCl) and incubated for 90 min, rotating at 4°C with 20 g of GST-RafRBD-K85A protein fused to Sepharose (50% suspension). Samples were washed three times with binding buffer before the beads were resuspended in 20 l of 2ϫ SDS-PAGE sample buffer. Proteins from the bead capture and 10 l of cleared supernatant were resolved on 15% acrylamide gels, blotted with anti-Ras or anti-HA (Rap) antisera and visualized by chemiluminescence. Blots were quantified by phosphorimaging. The amount of GTPRap or GTP-Ras captured by the GST-RafRBD-K85A beads was expressed as a percentage of the Ras or Rap present in the supernatant (estimated from the 10-l input). Expression of RasGRP2-Flag or MycCalDAG-GEFI was confirmed by immunoblotting using anti-Flag or anti-Myc antisera, respectively.
Cell Culture and Metabolic Labeling Assays-COS cells were transfected by electroporation and BHK cells by lipofection (36 (36) . Prior to harvesting for fractionation studies, COS cells were serum-starved for 4 -16 h as indicated. Hypotonic lysis, homogenization, and centrifugation were carried out as described previously (38) .
NIH3T3 Growth Assays-NIH3T3 cells were transfected using calcium phosphate precipitation as described (39) . To generate polyclonal populations, cells seeded on 10-cm plates were co-transfected with 1.5 g of pSV-hyg, together with 1.5 g of EXV expression plasmids for N-Ras, RasGRP2-Flag, Myc-CalDAG-GEFI, or empty vector. After 48 h, cultures were selected with 300 g/ml hygromycin. Surviving cells were pooled and grown continually in hygromycin. For growth assays, 10 4 cells (per well) were plated in multiwell dishes in DMEM containing 5%, 1%, or 0.1% serum. Cells were trypsinized and counted every 24 h for 4 days with each time point counted in triplicate. Three independent transfections were analyzed. Expression of RasGRP2-Flag or MycCalDAG-GEFI was confirmed by immunoblotting or indirect immunofluorescence using anti-Flag or anti-Myc antisera, respectively. Expression of N-Ras was verified by immunoblotting using Y13-259.
RESULTS

Identification of a Full-length cDNA for CalDAG-GEF1/Ras-GRP2-
The coding sequence for a human RasGEF was discovered during the generation of a transcript map of a region of human chromosome band 11q13 (31) . The gene, originally designated MCG7, was subsequently assigned the locus name RASGRP2 by the human genome project nomenclature committee. A cDNA corresponding to RASGRP2 was independently isolated by two other groups (29, 30) and subsequently characterized as a 609-amino acid RapGEF referred to as CalDAG-GEFI. However, during our independent isolation of a fulllength cDNA for RASGRP2, we identified an additional EST that contained sequence 5Ј to that previously reported to constitute the N terminus of CalDAG-GEFI (see "Experimental Procedures" for details). This additional sequence together with the general layout of the full-length RASGRP2 gene product is shown in Fig. 1 . The core exchange factor domains comprising the Ras exchange motif and the SCR1, SCR2, and SCR3 motifs plus the diacylglycerol binding (DGB) domain and EF hands have been described previously (27, 30) . A novel feature of the N terminus of full-length RasGRP2 is the presence of potential consensus sequences for co-translational myristoylation and posttranslational palmitoylation. Northern blot analysis showed that RASGRP2 was expressed predominantly as 2.4-kilobase pair transcripts in all tissues tested: heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. Expression was highest in heart, brain, and kidney as variously reported previously (29, 30) , but in contrast to the published data we also detected additional transcripts of 0.8 kilobase pairs in heart and 4.7 kilobase pairs in heart, lung, and placenta (results not shown). For the sake of brevity, we will refer to the short form of the RASGRP2 gene product as CalDAG-GEFI because this is the previously published name, and the full-length gene product as RasGRP2, after the name assigned to the gene by human genome project nomenclature committee.
RasGRP2 Is Palmitoylated and Myristoylated-The N-terminal sequence of full-length RasGRP2 comprises MGTQRLCGR. Although the common consensus sequences for myristoylation include serine or threonine at amino acid ϩ6, small hydrophobic residues are also tolerated, as in the myristoylation motifs of Arf, A kinase, Arg, and Abl. Moreover, the presence of cysteine at amino acid ϩ7 suggested that the N terminus of RasGRP2 may also be palmitoylated (40) . We therefore investigated whether RasGRP2 was lipid-modified in vivo. To this end, a Flag epitope was engineered onto the C terminus of the protein leaving the N-terminal sequences intact (ϭRasGRP2-Flag) (Fig. 1) . A second construct, which represents the shorter alternative spliced form of RasGRP2, was also engineered by replacing the N-terminal 62 amino acids of RasGRP2 with a Myc epitope (ϭMyc-CalDAG-GEFI). RasGRP2-Flag and MycCalDAG-GEFI were transiently expressed in COS cells and the relative hydrophobicity of the two proteins assessed in a Triton X-114 partitioning assay (41) . Fig. 2A shows that 60% of Ras-GRP2-Flag partitions into the detergent phase of Triton X-114, whereas Myc-CalDAG-GEFI partitions exclusively into the aqueous phase of Triton X-114. Thus, a significant proportion of RasGRP2-Flag is hydrophobic, whereas all Myc-CalDAG-GEFI is hydrophilic. This result is consistent with the N terminus of RasGRP2 being lipid-modified.
COS cells expressing RasGRP2-Flag or Myc-CalDAG-GEFI were then metabolically labeled with [ 
FIG. 2. RasGRP2 is lipid-modified and localizes to the plasma membrane.
A, lysates of COS cells expressing RasGRP2-Flag or MycCalDAG-GEFI were prepared in Triton X-114 and partitioned into detergent (D) and aqueous (Aq) phases as described (41) . Equal proportions of each phase were resolved by SDS-PAGE, immunoblotted with anti-Myc or anti-Flag antisera, and detected by enhanced chemiluminescence. Hydrophobic proteins partition into the detergent phase, whereas hydrophilic proteins partition into the aqueous phase of Triton X-114. By this analysis, RasGRP2 is significantly more hydrophobic than CalDAG-GEFI, consistent with the N terminus of RasGRP2 being lipid-modified. B, RasGRP2-Flag and Myc-CalDAG-GEFI proteins expressed in COS cells were metabolically labeled with [ 35 S]methionine (Met), [ 3 H]myristic acid (Mys), or [ 3 H]palmitic acid (Pl). Proteins were immunoprecipitated (IP) from cell lysates with anti-epitope antisera, resolved by SDS-PAGE, and visualized by fluorography. A duplicate of the tritium-labeled gel was soaked in 1 M hydroxylamine for 1 h prior to fluorography (ϩhydrox). RasGRP2-Flag incorporates label from both tritiated fatty acids, showing that it is co-translationally myristoylated and posttranslationally palmitoylated. Note that the palmitate but not the myristate label is released by hydroxylamine. CalDAG-GEFI, which lacks the consensus sites for these modifications, is labeled by neither fatty acid. C, RasGRP2-Flag and Myc-CalDAG-GEFI were expressed in BHK cells and visualized by indirect immunofluorescence using antiepitope antisera. Cells expressing RasGRP2-Flag show plasma membrane staining, whereas cells expressing CalDAG-GEFI show cytosolic staining.
quence (42) . To determine the subcellular localization of Ras-GRP2, BHK cells expressing RasGRP2-Flag or Myc-CalDAG-GEFI were examined using indirect immunofluorescence. Fig.  2C shows that RasGRP2-Flag localizes extensively to the plasma membrane, although there is also some soluble cytosolic staining. In contrast, Myc-CalDAG-GEFI is confined to the cytosol with no evidence of plasma membrane staining. Similarly, when COS cells expressing the epitope-tagged variants of RasGRP2 were fractionated and immunoblotted for the Flag or Myc epitopes, RasGRP2-Flag was found to be distributed approximately equally between the P100 (membrane) and S100 (cytosolic) fractions (Fig. 3) , consistent with the proportion shown to be lipidated by Triton X-114 partitioning ( Fig. 2A) . Myc-CalDAG-GEFI was found predominantly in the S100 fraction (Fig. 3) .
RasGRP has been shown to translocate from cytosol to membrane when cells are treated with 12-O-tetradecanoylphorbol-13-acetate (TPA) for 2 min (27, 28). We therefore examined whether TPA would affect the subcellular localization of Ras-GRP2. Fig. 3 shows that there was no detectable change in the subcellular distribution of either RasGRP2-Flag or MycCalDAG-GEFI in response to a 2-min exposure to either TPA or a calcium ionophor (A23187), or both agents together. However, a substantial proportion of Myc-CalDAG-GEFI did translocate to the P100 fraction when cells were treated with TPA for 15 min (Fig. 3) . The presence or absence of calcium ionophor during exposure to TPA did not significantly affect the translocation of Myc-CalDAG-GEFI (Fig. 3) . Prolonged exposure to TPA did not alter the subcellular distribution of RasGRP2 (data not shown).
RasGRP2 Selectively Activates N-and Ki-Ras but Not HaRas-We next investigated the ability of RasGRP2 to catalyze Ras nucleotide exchange in intact cells. COS cells were transfected with expression plasmids for wild type N-, Ki-, and Ha-Ras, alone and in combination with RasGRP2-Flag or MycCalDAG-GEFI. The cells were metabolically labeled with [ 32 P]orthophosphate and the relative amounts of GTP and GDP captured in anti-Ras immunoprecipitates determined by thin layer chromatography (TLC) and phosphorimaging. Fig. 4A shows that in the conditions of this assay RasGRP2-Flag stimulated GTP loading of N-Ras and Ki-Ras but not Ha-Ras. The -fold increase in GTP loading of N-Ras by RasGRP2 is of a similar magnitude to that reported recently on Ha-Ras by RasGRP (27). Importantly, in control experiments using cotransfected mSos1, Ha-Ras was efficiently loaded with GTP (to 21 Ϯ 1.65%, n ϭ 3) showing that Ha-Ras is competent for nucleotide exchange in this assay. In contrast, Myc-CalDAG-GEFI was unable to stimulate GTP loading of any Ras isoform, consistent with the findings of a previous study (30) . These results indicate that plasma membrane localization may be critical for the RasGEF activity of RasGRP2 in vivo.
The N-Ras exchange assays were then repeated, but cells were treated with TPA, A23187, or TPAϩA23187 for 2 or 15 min immediately prior to harvesting. Fig. 4 (B and C) shows that TPA enhanced and A23187 partially inhibited the GTP loading of N-Ras by RasGRP2-Flag. These opposing effects were additive on RasGRP2 exchange activity. The duration of exposure to TPA did not affect the degree of stimulation of FIG. 3 . CalDAG-GEFI translocates to the membrane fraction in response to prolonged exposure to TPA. Equivalent aliquots of COS cells expressing RasGRP2-Flag or Myc-CalDAG-GEFI were treated with A23187 (10 M) and/or TPA (100 nM), or Me 2 SO (control) for 2 or 15 min. The cells were harvested and equal proportions of each S100 (cytosolic, S) and P100 (membrane, P) fraction were immunoblotted with anti-Myc or anti-Flag antisera. Myc-CalDAG-GEFI is found predominantly in the S100 cytosolic fraction, whereas full-length RasGRP2-Flag is equally distributed between S100 and P100 fractions. Neither protein shows any significant change in subcellular distribution in response to a 2-min exposure to calcium ionophor or TPA or both agents together; however, the amount of CalDAG-GEFI found in the P100 fraction increases substantially after a 15-min exposure to TPA. The distribution of RasGRP2-Flag was unchanged after 15 min of exposure to TPA (data not shown).
FIG. 4. RasGRP2 functions as a RasGEF in vivo.
A, wild type Ki-Ras (B), N-Ras, or Ha-Ras proteins were transiently expressed in COS cells with and without RasGRP2-Flag or Myc-CalDAG-GEFI. The cells were metabolically labeled with [ 32 P]orthophosphate and Ras proteins immunoprecipitated; guanine nucleotides were eluted from the immunoprecipitates, resolved by TLC, and quantified by phosphorimaging. Duplicate aliquots of cells from each electroporation were analyzed by immunoblotting to confirm that all transfected proteins were equally expressed (data not shown). RasGRP2-Flag selectively loads N-Ras and Ki-Ras with GTP, whereas Myc-CalDAG-GEFI does not nucleotide exchange any Ras protein in vivo. B, COS cells expressing N-Ras with and without RasGRP2-Flag were metabolically labeled as in A and treated with A23187 (10 M) and/or TPA (100 nM) for 2 min prior to harvesting. The TLC plate from a representative experiment shows that the GEF activity of RasGRP2-Flag is up-regulated by TPA and down-regulated by an increase in intracellular calcium. C, the results from the experiment shown in panel B and three to five similar experiments in which cells were treated with A23187 and/or TPA for 2 or 15 min prior to harvesting. After 15 min of exposure to TPA, MycCalDAG-GEFI potently stimulates GTP loading of N-Ras. The control cells (Con) expressing N-Ras without exchange factors were incubated for 15 min with A23187 and/or TPA. DMSO, Me 2 SO.
RasGRP2 activity, but with more prolonged exposure to TPA, the inhibitory effect of A23187 was less marked. In contrast, Myc-CalDAG-GEFI did not stimulate GTP loading of N-Ras during a 2-min exposure to TPA, but a 15-min treatment with TPA did result in potent activation of Myc-CalDAG-GEFI NRas exchange activity (Fig. 4C) . As with RasGRP2, this TPAmediated stimulation of Myc-CalDAG-GEFI exchange activity was partially inhibited by A23187.
To further characterize CalDAG-GEFI, we evaluated exchange activity toward Ras in vitro. A GST fusion of CalDAG-GEFI was generated and incubated with recombinant N-Ras protein preloaded with radiolabeled GDP. Fig. 5 shows that, in the presence of excess cold GTP, CalDAG-GEFI catalyzed release of GDP from N-Ras whereas minimal loss of label occurred under control conditions. Thus, CalDAG-GEFI has guanine nucleotide exchange activity toward N-Ras in vitro. To investigate whether this GEF activity was sensitive to regulation by calcium or diacylglycerol, the exchange reactions were repeated in the presence of 2 mM calcium or 10 M TPA. Interestingly, calcium completely inhibited CalDAG-GEFI-catalyzed release of GDP from N-Ras, whereas TPA had no effect (Fig. 5) .
While this work was in progress, Kawasaki et al. (30) reported that CalDAG-GEFI has potent RapGEF activity. We therefore compared the RapGEF activity of RasGRP2 with that of CalDAG-GEFI. To this end we used a "pull-down" assay (43) , in which RapGTP is isolated from cell lysates using a GST fusion of the Raf-1 Ras binding domain (RBD) and quantified by immunoblotting. The RafRBD used in these experiments contains a K85A substitution, which increases Ͼ20-fold the amount of RasGTP or RapGTP that can be recovered from a cell lysate. 2 The pull-down assay was validated by evaluating the RasGEF activity of RasGRP2 and CalDAG-GEFI and yielded identical results to those obtained in the immunoprecipitation assay (data not shown). Fig. 6 shows that CalDAG-GEFI efficiently catalyzed GTP loading of Rap1 in COS cells and that this RapGEF activity was further stimulated by both TPA and calcium ionophor treatment of cells for 2 or 15 min prior to harvesting. In contrast, RasGRP2 was less potent than CalDAG-GEFI in catalyzing GTP loading of Rap1. The RapGEF activity of RasGRP2 was stimulated by 2 min of treatment with TPA or calcium ionophor, although these responses were less marked after 15 min of stimulation (Fig. 6B) .
RasGRP2 Stimulates the Growth of NIH3T3 Cells-We next examined whether overexpression of RasGRP2 in NIH3T3 cells would result in morphological transformation or accelerated growth, as has been shown for membrane-targeted Sos1 (8) . We found that neither RasGRP2-Flag nor Myc-CalDAG-GEFI gave rise to foci in NIH3T3 focus assays. Moreover, in co-transfection assays with RasGRP2-Flag and a hygromycin resistance 
FIG. 6. Comparison of the RapGEF activity of RasGRP2 and CalDAG-GEFI. A, COS cells expressing HA-Rap1 with and without
RasGRP2-Flag and Myc-CalDAG-GEFI were treated with TPA (100 nM) and/or A23187 (10 M) or Me 2 SO for 2 min prior to harvesting. Cells were lysed and HA-Rap1-GTP was isolated with GST-RafRBD-K85A-Sepharose beads as described under "Experimental Procedures." A representative immunoblot from one of these experiments is shown in panel A. In each lane, the HA-Rap1GTP captured is shown above an aliquot of the total HA-Rap1 present in the binding reaction (see "Experimental Procedures" for details). Greater quantities of HA-Rap1GTP are present when Myc-CalDAG-GEFI is co-expressed than when HARap1 is expressed by itself or with RasGRP2-Flag. 2-min incubations with A23187 and/or TPA stimulate the GTP loading of HA-Rap1 by either Myc-CalDAG-GEFI or RasGRP2-Flag. RasGRP2-Flag and MycCalDAG-GEFI expression was confirmed by immunoblotting using anti-epitope antisera. B, the results from the assay shown in panel A and from three to six similar experiments in which cells were stimulated for 2 or 15 min with TPA or A23187 were quantified. Myc-CalDAG-GEFI is a significantly more potent activator of HA-Rap1 than RasGRP2-Flag. After 2 min of incubation with the chemical modulators, the GTP loading of HA-Rap1 by Myc-CalDAG-GEFI is up-regulated by TPA and A23187, and this effect is additive when both chemicals are administered together. A similar profile is seen after 15-min incubations. Ras-GRP2-Flag is a weaker RapGEF than Myc-CalDAG-GEFI, but its activity is still excited by a 2-min stimulation with TPA and to a lesser extent by A23187. 15-min incubations with these modulators have less potent effects on RasGRP2 than 2-min incubations. Con, control; DMSO, Me 2 SO.
vector, hygromycin-resistant colonies appeared no different in morphology than vector transfected controls, despite clear expression of RasGRP2-Flag by Western blotting (data not shown). Similarly, assays of growth in reduced serum (5%, 1%, and 0.1%) revealed no differences in growth rates between polyclonal cell populations expressing RasGRP2-Flag or MycCalDAG-GEFI over vector-transfected controls (data not shown). Given the Ras isoform selectivity of RasGRP2, we repeated these experiments in NIH3T3 cells co-transfected with a low level of wild type N-Ras plasmid sufficient to give approximately 3-fold overexpression of N-Ras over endogenous levels. Fig. 7 (A and B) shows that polyclonal cell populations expressing wild type N-Ras had a growth rate approximately twice that of empty vector transfected control cell populations, but that co-expression of RasGRP2-Flag increased this growth rate another 3-fold. Somewhat unexpectedly, co-expression of Myc-CalDAG-GEFI in the N-Ras-expressing cells also resulted in an increment in growth rate (Fig. 7, A and B) . A possible explanation of this result is shown in Fig. 7 (C and D) . The biochemical assays of RasGRP2 function all required a period of serum starvation; therefore, the cell fractionation and immunofluorescence studies in Figs. 2 and 3 were performed under these conditions. However, Fig. 7C shows that continuous growth in serum, or a 2-min treatment with 20% serum after a period of serum-free growth, significantly increased the amount of Myc-CalDAG-GEFI associated with the P100 fraction. In contrast, there was no effect of serum on the subcellular distribution of RasGRP2-Flag (data not shown). Thus, in the conditions of the growth rate assays in Fig. 7 (A and B) , carried out in 5% serum, a substantial amount of Myc-CalDAG-GEFI becomes membrane-associated (Fig. 7C) . In the light of this observation, the serum response of Myc-CalDAG-GEFI was evaluated in COS cells. Fig. 7D shows that serum is a potent activator of the RasGEF activity of CalDAG-GEFI toward NRas but has minimal effect on the RasGEF activity of RasGRP2-Flag.
DISCUSSION
In this paper we describe the cloning and characterization of RasGRP2, a longer isoform of CalDAG-GEFI. The basic domain structure of RasGRP2/CalDAG-GEFI is similar to that of the related protein RasGRP/CalDAG-GEFII, which has been described previously. One structural feature not commented on in the original description of CalDAG-GEFI is the presence of a short coiled-coil (CC) domain located between the Ras exchange motif and SCR1 box. This is not present in RasGRP, which instead has a more extensive CC domain in a C-terminal extension that is absent from CalDAG-GEFI. The role of the CC domains in RasGRP and RasGRP2 is unknown. In RasGRF1 a CC domain co-operates with IQ and pleckstrin homology domains for maximal stimulation of exchange activity by calmodulin-complexed calcium (23) , but since the RasGRPs lack these other domains and RasGRP2 activity is inhibited by calcium, the CC domain must have some other role.
The novel N-terminal sequences present in RasGRP2 contain acylation sites that we show here are both N-myristoylated . These curves show growth in 5% serum; essentially identical results were obtained in 1% serum (data not shown). B, growth rates, relative to the vector-transfected control populations (ϭ1), derived from the growth curves shown in panel A. C, subcellular fractionation of cells expressing Myc-CalDAG-GEFI following growth in serum (ϩ), 16 h of serum-free growth (Ϫ), or 16 h of serum-free growth followed by a 2-min add-back (AB) of 20% serum prior to harvesting. Equal proportions of S100 (S) and P100 (P) fraction were immunoblotted (IB) with anti-Myc antisera. D, COS cells expressing N-Ras with and without RasGRP2-Flag and Myc-CalDAG-GEFI were serum-starved for 16 h and then harvested directly (ϪBCS) or treated for 2 min with 20% bovine calf serum (ϩBCS) prior to harvesting. Con, control. RasGTP levels were measured in a GST-RafRBD-K85A pull-down assay. The graph shows a representative experiment that was repeated two further times. The presence of serum potently stimulates CalDAG-GEFI RasGEF activity toward N-Ras. Expression of CalDAG-GEFI and RasGRP2-Flag was confirmed by immunoblotting with anti-Myc or anti-Flag antisera, respectively. and palmitoylated. The most likely site for palmitoylation is Cys-7, since this is the only cysteine residue in the N-terminal 70 amino acids of RasGRP2. We cannot exclude a more remote palmitoylation site, but palmitoylation of other N-myristoylated proteins is usually close to the N terminus (40) . The results of the Triton X-114 assay indicate that only 60% of RasGRP2-Flag expressed in COS cells undergoes lipid modification. Since co-translational myristoylation precedes posttranslational palmitoylation, it is likely that this result reflects incomplete myristoylation of RasGRP2. We have observed previously that myristoylation of proteins overexpressed in COS cells can be incomplete (37) ; this, coupled with the slightly atypical myristoylation motif, probably accounts for the incomplete acylation of RasGRP2. The N-terminal sequence of Ras-GRP also contains a potential N-myristoylation site, but it has not yet been determined whether RasGRP is acylated (28) . RasGRP2 is localized extensively to the plasma membrane in contrast to CalDAG-GEFI, which is almost exclusively cytosolic in quiescent cells. These data clearly implicate the N-terminal 60 amino acids of full-length RasGRP2 as containing a plasma membrane localization motif. Since the combination of myristoylation and palmitoylation is well established as a targeting signal (44), we propose that dual acylation targets RasGRP2 to the plasma membrane.
CalDAG-GEFI has been reported to be a RapGEF with no RasGEF activity (30) . We show here, however, that CalDAG-GEFI is indeed a RasGEF, albeit with an isoform specificity that is restricted to N-and Ki-Ras. Ha-Ras was the only Ras isoform tested by Kawasaki et al. (30) , and we are in full agreement with the conclusions of their study that CalDAG-GEFI cannot activate this Ras isoform. More intriguingly, CalDAG-GEFI and RasGRP2 have different basal exchange activities and show distinct in vivo responses to stimulation by TPA and calcium. CalDAG-GEFI has potent RapGEF activity, which is stimulated both by acute elevations of cytosolic calcium and exposure to TPA, but it has almost no N-Ras GEF activity until subject to prolonged stimulation by TPA or acute stimulation by serum. The TPA-stimulated RasGEF activity of CalDAG-GEFI is inhibited by elevations of cytosolic calcium. In contrast, RasGRP2 is a less potent RapGEF but a more potent RasGEF than CalDAG-GEFI. The RapGEF activity of Ras-GRP2 is stimulated by TPA and calcium, whereas the RasGEF activity is stimulated by TPA, but inhibited by calcium.
The activation of RasGEF activity in CalDAG-GEFI by TPA or serum stimulation correlates temporally with translocation of CalDAG-GEFI to the plasma membrane. We propose therefore that this major change in subcellular localization is fundamental to Ras activation by CalDAG-GEFI, analogous to the mechanisms described for Sos1 and RasGRF2. Similarly, there is a significant translocation of RasGRP to the plasma membrane in response to TPA treatment, concomitant with the stimulation of RasGEF activity (27). RasGRP2 has constitutive RasGEF activity, presumably reflecting constitutive plasma membrane localization. However, in contrast to CalDAG-GEFI and RasGRP, there is no detectable change in the subcellular distribution of RasGRP2 to correspond with TPA stimulation of RasGEF activity.
Is there a common mechanism underlying these TPA effects? The DGB domain of RasGRP is clearly responsible for TPAmediated membrane translocation because deletion of the domain blocks RasGRP membrane binding (27) and the isolated DGB domain can target heterologous proteins to the plasma membrane in a TPA-dependent manner (28) . The DGB domain of CalDAG-GEFI can effect a similar change in subcellular localization, since TPA treatment results in membrane translocation of CalDAG-GEFI, albeit with different kinetics from RasGRP; RasGRP is translocated within 2 min, whereas 15 min of TPA treatment is needed to bring CalDAG-GEFI to the cell membrane. Taking these data together, we propose that, although RasGRP2 is localized at the plasma membrane, it may in part be sequestered away from Ras until interactions between TPA and the DGB domain relocate RasGRP2 to a different plasma membrane microdomain. The mechanism for the effects of TPA could then be the same for RasGRP, CalDAG-GEFI, and RasGRP2, namely to co-localize the Ras-GEF and Ras substrate in the same plasma membrane microdomain. In support of this model, it is interesting to note that the GEF activity of RasGRP was highest when it was membrane-targeted using a Ras localization signal (28), a strategy that should exactly co-localize Ras and RasGRP in the same microdomain. An alternative explanation that the TPA stimulates RasGRP2 via an allosteric effect seems unlikely, since stimulation was not evident in vitro even with high concentrations of TPA. Serum stimulation caused a much more rapid membrane translocation and activation of CalDAG-GEFI than TPA, perhaps reflecting selective generation of diacylglycerol in physiologically relevant plasma membrane microdomains, rather than general loading of cell membranes with DGB binding sites.
RasGRP2 selectively activates N-Ras and Ki-Ras, but not Ha-Ras. In contrast, RasGRP activates Ha-Ras and mRasGRP when co-transfected with N-, K-, or Ha-Ras results in mitogenactivated protein kinase activation, consistent with activation of all three isoforms (27, 28) . One explanation of these data is simply that sequence differences between RasGRP and Ras-GRP2 result in different substrate specificities. An alternative hypothesis invokes recent work showing that Ras isoforms operate in functionally distinct microdomains of the plasma membrane (45); signaling by Ha-Ras, anchored to the plasma membrane by palmitoylation and farnesylation, is dependent on the integrity of cholesterol-rich microdomains, whereas signaling by Ki-Ras, anchored by a charged polybasic domain and farnesylation, does not require lipid rafts. In this context, the different Ras isoform specificity of RasGRP2 and RasGRP may be explained by postulating that RasGRP2 gains access only to the N-and Ki-Ras microdomains because N-terminal palmitoylation imposes a restraint on RasGRP2 mobility within the plasma membrane that is not experienced by RasGRP.
Somewhat surprisingly, moderate overexpression of plasma membrane-localized RasGRP2 did not morphologically transform NIH3T3 cells, although we were able to show an N-Rasdependent stimulation of cell growth by both RasGRP2 and CalDAG-GEFI. In fibroblasts, activated Rap can partially antagonize Ras transforming activity (46) . It is therefore tempting to speculate that the lack of transforming ability of Ras-GRP2 and CalDAG-GEFI may reflect their co-activation of Ras and Rap. In this context it is worth noting that, since calcium inhibits the RasGEF activity of RasGRP2/CalDAG-GEFI while stimulating the RapGEF activity, a calcium signal effectively shifts the GEF activity of RasGRP2 and CalDAG-GEFI from Ras to Rap. Together, these observations therefore reveal an interesting and novel molecular mechanism for utilizing a single exchange factor to co-ordinate Ras and Rap signaling events.
